4th International Conference on Neurology and Brain Disorders

November 19-21, 2020 | Rome, Italy

Holiday Inn Rome Aurelia
Via Aurelia, Km 8.400, 00165
Rome, Italy
Phone : 1 (702) 988 2320
Toll Free: 1800–883-8082
Whatsapp: +1 (540) 709-1879
Email: neurology@magnusscigroup.com
November 19-21, 2020 | Rome, Italy

Roberto Di Maio

Committee Member for Neurology Conference - Roberto Di Maio
Roberto Di Maio
Pittsburgh Institute for Neurodegenerative Diseases – Department of Neurology – School of Medicine – University of Pittsburgh, Pittsburgh – PA – United States
Title : Mitochondria-NADPH Oxidase 2 Interplay: Relevance in Parkinson’s Disease

Abstract:

Oxidative stress has been described as a major cause of nigrostriatal degeneration in familial and idiopathic Parkinson’s disease (PD). Moreover, NADPH oxidase 2 (NOX2) and the mitochondrial electron transport chain, the major enzymatic sources of reactive oxygen species (ROS) in neural cells, appear intimately related in a redox regulatory pathway recently termed “ROS-induced ROS production”. While there is some evidence that NOX2 inhibitors may protect dopaminergic neurons against degeneration, these studies have often been hampered by the lack of highly specific inhibitors. Additionally, it has been difficult to assess the activation state of NOX2 under experimental or pathological conditions with a cellular level of resolution. We now report testing of a novel and highly specific NOX2 inhibitor, NOX2ds-tat, and development of a new proximity ligation histological assay for NOX2 activation. By utilizing this novel histological PL assay and NOX2ds-tat, for the first time, we characterized the nature of the interplay between NOX2 and mitochondria in PD progression. Specifically, we found that NOX2 is hyperactive in idiopathic PD and the rotenone rat model of PD. Moreover, NOX2 activity contributes to (i) ?-synuclein accumulation/aggregation (ii) impairment of the mitochondrial protein import machinery (iii) altered redox status of HSP70 (iv) disruption of the interaction between HSP70 and the TOM complex receptor, TOM70, with the consequence of PINK1:TOM70 interaction. Overall, the data suggest that targeting NOX2 may constitute a therapeutic approach in prevention of PD progression.

Audience Take Away: 

•    The findings of this study highlight the critical role of a novel PD-relevant feed-forward pathogenic pathway where NOX2-mitochondria interplay is the key factor. 
•    The audience will have the opportunity to acquire knowledge on these novel pathogenic mechanisms of PD as potential therapeutic targets. 
•    The presentation will provide to the audience the potential of developing new studies in the topic.   
•    In this study we developed novel techniques able to detect protein-protein interaction or protein post translational modifications (i.e. phosphorylation) with cellular resolution. These novel experimental approaches allowed us to detect in vitro and in vivo NOX2 and LRRK2 activity status and provide evidence of relevance in the human disease. We are disseminating these novel techniques to the scientific community to provide practical solutions able to improve and simplify the experimental approaches.

Biography:

Dr. Di Maio studied Biomedicine at the University of Palermo (Italy) and graduated in 1991. In 1993, he joined the Mario Negri Sud Research Institute, (Italy) where he obtained his master’s degree in Pharmacology in 1996. He then joined the research group of Prof. Vittorio La Grutta at the Institute of Human Physiology, University of Palermo (Italy) where he received his PhD degree in Neurosciences in 2005. After three years of postdoctoral fellowship supervised by Dr. Greenamyre at the Pittsburgh Institute for Neurodegenerative Diseases (University of Pittsburgh, Pittsburgh – USA), He has been appointed as Assistant Professor at the same Institution. He has published more than 40 research articles in SCI(E) journals.

Watsapp